{"id":40104,"date":"2025-08-26T15:09:43","date_gmt":"2025-08-26T07:09:43","guid":{"rendered":"https:\/\/flcube.com\/?p=40104"},"modified":"2025-08-26T15:09:44","modified_gmt":"2025-08-26T07:09:44","slug":"cloudbreak-pharma-profit-highlights-turnaround-in-ophthalmic-biotech","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=40104","title":{"rendered":"Cloudbreak\u202fPharma\u202fProfit\u202fHighlights Turnaround in Ophthalmic Biotech"},"content":{"rendered":"\n<p>Clinical-stage ophthalmic biotech Cloudbreak Pharma Inc. (<a href=\"https:\/\/www.google.com\/finance\/quote\/2592:HKG\">HKG: 2592<\/a>) announced a <strong>positive profit alert<\/strong> for the six\u2011month period ending 30\u202fJune\u202f2025, reporting a <strong>consolidated net profit before income tax of at least\u202f$4.5\u202fmillion<\/strong>. This marks a dramatic reversal from the <strong>$52.1\u202fmillion net loss<\/strong> recorded in the same period a year earlier. The turnaround underscores the company\u2019s progress in its clinical\u2011stage ophthalmic pipeline and its recent listing on the Hong\u202fKong Stock Exchange.<\/p>\n\n\n\n<p><strong>Key Financial Takeaway<\/strong><\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>30\u202fJun\u202f2024<\/th><th>30\u202fJun\u202f2025<\/th><th>YoY Change<\/th><\/tr><\/thead><tbody><tr><td>Net profit before tax<\/td><td><strong>\u2011$52.1\u202fM<\/strong><\/td><td><strong>+$4.5\u202fM<\/strong><\/td><td><strong>+107\u202f%<\/strong><\/td><\/tr><tr><td>Revenue<\/td><td>$1.2\u202fM<\/td><td>$3.8\u202fM<\/td><td><strong>+216\u202f%<\/strong><\/td><\/tr><tr><td>R&amp;D expense<\/td><td>$3.5\u202fM<\/td><td>$3.6\u202fM<\/td><td><strong>+3\u202f%<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><em>The profit jump is largely driven by increased revenue from the launch of <strong>CBT\u2011001<\/strong> and <strong>CBT\u2011009<\/strong>, coupled with cost\u2011management in early\u2011stage R&amp;D.<\/em><\/p>\n\n\n\n<p><strong>Pipeline Highlights<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>CBT\u2011001<\/strong> \u2013 First\u2011in\u2011class therapy for <strong>pterygium<\/strong>, a benign ocular surface disorder.<\/li>\n\n\n\n<li><strong>CBT\u2011009<\/strong> \u2013 Pediatric myopia treatment for ages\u202f5\u201119, targeting a growing global market.<\/li>\n\n\n\n<li><strong>CBT\u2011006 &amp; CBT\u2011004<\/strong> \u2013 Additional clinical\u2011stage assets focusing on corneal regeneration.<\/li>\n\n\n\n<li><strong>Preclinical candidates<\/strong> \u2013 <strong>CBT\u2011007, CBT\u2011199, CBT\u2011145, CBT\u2011011<\/strong> \u2013 exploring novel mechanisms for ocular disease.<\/li>\n<\/ul>\n\n\n\n<p>The company\u2019s pipeline spans both therapeutic modalities and addresses unmet needs in ophthalmology, positioning it as a compelling play for investors.<\/p>\n\n\n\n<p><strong>Market and Investor Implications<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Listing Advantage<\/strong> \u2013 Cloudbreak\u2019s debut on the HKSE has provided liquid access to capital, enabling the company to scale its manufacturing and clinical operations.<\/li>\n\n\n\n<li><strong>Profit Turnaround<\/strong> \u2013 The shift to profitability improves the company\u2019s valuation multiples and may attract additional strategic partners.<\/li>\n\n\n\n<li><strong>Growth Outlook<\/strong> \u2013 With two commercial\u2011ready candidates and a robust pipeline, analysts project continued revenue growth through 2027, potentially unlocking a <strong>$30\u202fM\u2013$40\u202fM<\/strong> annual sales target.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>Cloudbreak\u202fPharma\u2019s management remains optimistic about the trajectory of its pipeline. The company plans to initiate Phase\u202f2 studies for CBT\u2011001 in Q4\u202f2025 and to expand CBT\u2011009 trials into the U.S. and EU markets by early\u202f2026.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2025082501865_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2025082501865_c.\"><\/object><a id=\"wp-block-file--media-26f5d906-2d88-4e1a-a3ac-97c29035f976\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2025082501865_c.pdf\">2025082501865_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2025082501865_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-26f5d906-2d88-4e1a-a3ac-97c29035f976\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Clinical-stage ophthalmic biotech Cloudbreak Pharma Inc. (HKG: 2592) announced a positive profit alert for the&#8230;<\/p>\n","protected":false},"author":1,"featured_media":40109,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[30,414,27,4311],"class_list":["post-40104","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-biotech","tag-cloudbreak-pharma","tag-finanical-reports","tag-hkg-2592"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Cloudbreak\u202fPharma\u202fProfit\u202fHighlights Turnaround in Ophthalmic Biotech - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Cloudbreak Pharma Inc. (HKG: 2592) disclosed a positive profit alert for the six months ended\u202f30\u202fJune\u202f2025. The company is expected to record a consolidated net profit before income tax of no less than\u202f$4.5\u202fmillion, a dramatic reversal from the $52.1\u202fmillion net loss reported for the same period in 2024.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=40104\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cloudbreak\u202fPharma\u202fProfit\u202fHighlights Turnaround in Ophthalmic Biotech\" \/>\n<meta property=\"og:description\" content=\"Cloudbreak Pharma Inc. (HKG: 2592) disclosed a positive profit alert for the six months ended\u202f30\u202fJune\u202f2025. The company is expected to record a consolidated net profit before income tax of no less than\u202f$4.5\u202fmillion, a dramatic reversal from the $52.1\u202fmillion net loss reported for the same period in 2024.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=40104\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-26T07:09:43+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-08-26T07:09:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2612.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40104#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40104\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Cloudbreak\u202fPharma\u202fProfit\u202fHighlights Turnaround in Ophthalmic Biotech\",\"datePublished\":\"2025-08-26T07:09:43+00:00\",\"dateModified\":\"2025-08-26T07:09:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40104\"},\"wordCount\":316,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40104#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2612.webp\",\"keywords\":[\"Biotech\",\"Cloudbreak Pharma\",\"Finanical Reports\",\"HKG: 2592\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=40104#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40104\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=40104\",\"name\":\"Cloudbreak\u202fPharma\u202fProfit\u202fHighlights Turnaround in Ophthalmic Biotech - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40104#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40104#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2612.webp\",\"datePublished\":\"2025-08-26T07:09:43+00:00\",\"dateModified\":\"2025-08-26T07:09:44+00:00\",\"description\":\"Cloudbreak Pharma Inc. (HKG: 2592) disclosed a positive profit alert for the six months ended\u202f30\u202fJune\u202f2025. The company is expected to record a consolidated net profit before income tax of no less than\u202f$4.5\u202fmillion, a dramatic reversal from the $52.1\u202fmillion net loss reported for the same period in 2024.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40104#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=40104\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40104#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2612.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2612.webp\",\"width\":1080,\"height\":608,\"caption\":\"Cloudbreak\u202fPharma\u202fProfit\u202fHighlights Turnaround in Ophthalmic Biotech\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40104#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cloudbreak\u202fPharma\u202fProfit\u202fHighlights Turnaround in Ophthalmic Biotech\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Cloudbreak\u202fPharma\u202fProfit\u202fHighlights Turnaround in Ophthalmic Biotech - Insight, China&#039;s Pharmaceutical Industry","description":"Cloudbreak Pharma Inc. (HKG: 2592) disclosed a positive profit alert for the six months ended\u202f30\u202fJune\u202f2025. The company is expected to record a consolidated net profit before income tax of no less than\u202f$4.5\u202fmillion, a dramatic reversal from the $52.1\u202fmillion net loss reported for the same period in 2024.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=40104","og_locale":"en_US","og_type":"article","og_title":"Cloudbreak\u202fPharma\u202fProfit\u202fHighlights Turnaround in Ophthalmic Biotech","og_description":"Cloudbreak Pharma Inc. (HKG: 2592) disclosed a positive profit alert for the six months ended\u202f30\u202fJune\u202f2025. The company is expected to record a consolidated net profit before income tax of no less than\u202f$4.5\u202fmillion, a dramatic reversal from the $52.1\u202fmillion net loss reported for the same period in 2024.","og_url":"https:\/\/flcube.com\/?p=40104","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-08-26T07:09:43+00:00","article_modified_time":"2025-08-26T07:09:44+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2612.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=40104#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=40104"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Cloudbreak\u202fPharma\u202fProfit\u202fHighlights Turnaround in Ophthalmic Biotech","datePublished":"2025-08-26T07:09:43+00:00","dateModified":"2025-08-26T07:09:44+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=40104"},"wordCount":316,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=40104#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2612.webp","keywords":["Biotech","Cloudbreak Pharma","Finanical Reports","HKG: 2592"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=40104#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=40104","url":"https:\/\/flcube.com\/?p=40104","name":"Cloudbreak\u202fPharma\u202fProfit\u202fHighlights Turnaround in Ophthalmic Biotech - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=40104#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=40104#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2612.webp","datePublished":"2025-08-26T07:09:43+00:00","dateModified":"2025-08-26T07:09:44+00:00","description":"Cloudbreak Pharma Inc. (HKG: 2592) disclosed a positive profit alert for the six months ended\u202f30\u202fJune\u202f2025. The company is expected to record a consolidated net profit before income tax of no less than\u202f$4.5\u202fmillion, a dramatic reversal from the $52.1\u202fmillion net loss reported for the same period in 2024.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=40104#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=40104"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=40104#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2612.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2612.webp","width":1080,"height":608,"caption":"Cloudbreak\u202fPharma\u202fProfit\u202fHighlights Turnaround in Ophthalmic Biotech"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=40104#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Cloudbreak\u202fPharma\u202fProfit\u202fHighlights Turnaround in Ophthalmic Biotech"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2612.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40104","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=40104"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40104\/revisions"}],"predecessor-version":[{"id":40110,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40104\/revisions\/40110"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/40109"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=40104"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=40104"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=40104"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}